Register now – June 13, 2024: This webinar will provide a brief history of the FDA’s interest in LDTs and review the new requirements in detail, serving as an introduction to medical device regulations in the context of a clinical laboratory.
Mayo Clinic Laboratories introduces an advancement in the management of Crohn's disease with the release of a new laboratory test that measures Risankizumab levels in patients. This test will advance the therapeutic monitoring of Crohn's disease, enabling personalized treatment approaches.
As we prepare to celebrate this year's Lab Week, the Mayo Collaborative Services Education team not only wants to highlight your important work as medical laboratory professionals and pathologists, but also help you feel more confident in your role by sharing the following educational resources that may give you additional knowledge and opportunities to advance in your career.
Medical Laboratory Professionals Week, also known as Lab Week, provides us with the opportunity to increase our understanding of and appreciation for clinical laboratory personnel. We celebrate their efforts to provide critical answers for patients every day and drive innovation in the field of medicine.
Short, interactive case studies from Mayo Clinic physicians, scientists, and allied health staff
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, to discuss tick-borne diseases and the latest testing options.
Mayo Clinic Laboratories introduces the Inherited Parkinson’s Disease Gene Panel (Mayo ID: PARDP), a collaborative breakthrough poised to transform Parkinson’s disease diagnosis and treatment. Led by Rodolfo Savica, M.D., Ph.D., and Zhiyv (Neal) Niu, Ph.D., this comprehensive test offers unparalleled insights into Parkinson’s genetics, unveiling novel gene associations and enhancing diagnostic precision through next-generation sequencing. The panel’s capabilities include detecting subtle genetic variations and identifying familial patterns, promising personalized medicine advancements.
Alicia Algeciras-Schimnich, Ph.D., discusses Mayo Clinic Laboratories’ new noninvasive plasma biomarker assay for Alzheimer’s disease, an accessible, highly accurate testing option for individuals age 50 and above who are experiencing mild cognitive impairment or early dementia. Positive test results can confirm amyloid beta pathology and facilitate access to disease-modifying therapies.
This week's research roundup feature: Intrathecal delivery of autologous culture-expanded adipose tissue-derived mesenchymal stem cells (AD-MSC) could be utilized to treat traumatic spinal cord injury (SCI). This Phase I trial (ClinicalTrials.gov: NCT03308565) included 10 patients with American Spinal Injury Association Impairment Scale (AIS) grade A or B at the time of injury.
Mayo Clinic Laboratories is thrilled to participate in the American Academy of Neurology (AAN) Annual Meeting, which will be held in Denver on April 13–17, 2024.
BioPharma Diagnostics executives will attend the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit, set to take place in Boston, Massachusetts, from April 23 –25. They will be available to meet with attendees to discuss how our capabilities and data can accelerate biopharmaceutical and clinical research initiatives.
Register now –May 8, 2024: This webinar will cover the laboratory tests available at Mayo Clinic Laboratories to monitor patients using monoclonal antibody therapies for treatment of inflammatory bowel disease. Focus will be shared between analytical approaches as well as literature and practice recommendations for test results interpretation.